Companies › Generate Biomedicines
3 active drug programs in 5 registered trials: 3 Phase 1, 2 Phase 3; Respiratory, Immunology, Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| GB-0895 | – | Phase 3 | Severe Asthma; Asthma | May 2027 |
| GB-7624 | – | Phase 1 | Atopic Dermatitis (AD) | Dec 2026 |
| GB-4362 Monoclonal antibody that binds and neutralizes free monomethyl auristatin E (MMAE) | – | Phase 1 | Advanced Urothelial Cancer | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06920693 | GB-7624 | Phase 1 | Atopic Dermatitis (AD) | Immunology | Dec 2026 |
| NCT07116889 | GB-0895 | Phase 1 | Asthma | Respiratory | May 2027 |
| NCT07484022 | GB-4362 | Phase 1 | Advanced Urothelial Cancer | Oncology | Jun 2027 |
| NCT07276724 | GB-0895 | Phase 3 | Severe Asthma | Respiratory | Dec 2028 |
| NCT07359846 | GB-0895 | Phase 3 | Severe Asthma | Respiratory | Jan 2029 |
Cash and short-term investments of $457m on 2026-06-30; operating cash outflow about $281m a year; runway about 20 months at that burn, to Feb 2028; 0 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Fate Therapeutics Kura Oncology Suzhou Zelgen Biopharmaceuticals Eikon Therapeutics Arcus Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.